Still on the Shelf: The Evidence, the Warnings, and the Policy Logic Keeping Ciprofloxacin in American Medicine

Few drugs in modern American pharmacology occupy as contested a position as ciprofloxacin. Since its FDA approval in 1987, the fluoroquinolone antibiotic has accumulated a safety record that would, in almost any other therapeutic class, prompt serious questions about market viability. Tendon ruptures. Peripheral neuropathy. Aortic aneurysm and dissection. Serious psychiatric disturbances. Each of these adverse events carries its own FDA black box warning or safety communication — and yet ciprofloxacin remains one of the most prescribed antibiotics in the United States, dispensed tens of millions of times annually.

Understanding why requires moving beyond simple outrage or simple dismissal. The answer lies in a complex intersection of pharmacology, epidemiology, regulatory philosophy, clinical necessity, and institutional inertia — a paradox that drug safety experts, prescribers, and patient advocates have been wrestling with for more than two decades.

A Safety Profile That Accumulated Gradually

Ciprofloxacin's adverse event history did not arrive as a single, disqualifying revelation. It built incrementally, each signal emerging years or even decades after the drug entered widespread use. The tendon rupture signal — particularly Achilles tendon rupture — was recognized in European literature during the 1990s and formally acknowledged by the FDA in 2008 with a black box warning. Peripheral neuropathy, which can be permanent, received its own black box addition in 2013. Warnings about aortic aneurysm and dissection followed in 2018, based on epidemiological studies suggesting a two- to threefold increase in risk among fluoroquinolone users.

This pattern of incremental discovery is not unusual in pharmacovigilance. It reflects the fundamental limitation of pre-approval clinical trials: they are powered to detect efficacy, not to identify rare or delayed adverse events in the broader population. The fluoroquinolone safety story is, in many respects, a textbook illustration of how post-market surveillance functions — and of its limitations.

Critically, none of these signals emerged as sudden catastrophic events affecting large proportions of users. The absolute risks, while clinically meaningful, remain low in the general population. Tendon rupture occurs in an estimated 0.1 to 0.4 percent of fluoroquinolone users. Aortic dissection risk, while elevated, translates to a small absolute number of additional cases per hundred thousand prescriptions. This statistical reality is central to why the FDA has responded with enhanced labeling rather than withdrawal.

The Regulatory Logic of Risk-Benefit Analysis

The FDA does not withdraw drugs because they cause harm in some patients. It withdraws drugs when the harm outweighs the benefit across the relevant patient population — or when safer alternatives exist for all indicated uses. Ciprofloxacin fails neither test convincingly enough to trigger removal.

For several of ciprofloxacin's approved indications, no equally effective oral alternative exists. Complicated urinary tract infections caused by multidrug-resistant gram-negative organisms, serious Pseudomonas aeruginosa infections, inhalational anthrax post-exposure prophylaxis, certain cases of plague — these are not indications where a clinician can simply substitute trimethoprim-sulfamethoxazole or a macrolide. The drug's activity against gram-negative pathogens, its oral bioavailability approaching intravenous administration, and its tissue penetration into sites like the prostate and bone give it a pharmacological profile that remains genuinely difficult to replicate.

From a regulatory standpoint, withdrawing ciprofloxacin would not eliminate the infections it treats. It would eliminate a tool for treating them, potentially shifting patients toward less effective therapies, intravenous-only alternatives, or — in some cases — inadequately treated infections. The FDA's risk management approach therefore centers on restricting use through labeling, not eliminating use entirely.

The 2016 FDA Drug Safety Communication advising against fluoroquinolone use for uncomplicated infections such as sinusitis, bronchitis, and uncomplicated UTIs represents this philosophy in action. Rather than withdrawal, the agency attempted to reshape prescribing behavior at the margin — reserving the drug for cases where the benefit is more clearly proportionate to the risk.

Why Prescribing Patterns Resist Policy Signals

If the regulatory intent is to narrow ciprofloxacin's use to genuinely high-need scenarios, the clinical reality in the United States has not fully cooperated. Studies published in journals including JAMA Internal Medicine and Annals of Internal Medicine consistently show that fluoroquinolones continue to be prescribed for indications — acute sinusitis, mild community-acquired pneumonia, uncomplicated cystitis in younger women — where the 2016 guidance explicitly recommended against their use.

Several forces sustain this gap between guidance and practice. Familiarity is among the most powerful. Ciprofloxacin has been in clinical use for nearly forty years. Generations of physicians trained during its ascendancy, and prescribing habits formed in residency are notoriously resistant to revision. The drug's broad spectrum provides a kind of clinical insurance against diagnostic uncertainty: when a clinician is not entirely sure what organism is causing an infection, a fluoroquinolone covers a wide range of possibilities.

Generic pricing reinforces the pattern. Ciprofloxacin is among the least expensive oral antibiotics available in the United States, with a standard course often costing less than ten dollars at major pharmacy chains. Economic barriers to prescribing it are essentially nonexistent, while the economic and logistical costs of switching to narrower-spectrum alternatives — which may require culture and sensitivity data the clinician does not yet have — are real.

Electronic health record defaults, formulary placement, and the persistent underrepresentation of antibiotic stewardship resources in outpatient settings compound these dynamics. Changing prescribing behavior at scale requires more than FDA label updates; it requires sustained, multifaceted stewardship infrastructure that remains unevenly distributed across the US healthcare system.

What the Adverse Event Data Actually Show — and What They Do Not

A rigorous reading of the adverse event literature on ciprofloxacin requires careful attention to what the studies can and cannot establish. Most of the epidemiological data linking fluoroquinolones to aortic dissection, for example, come from retrospective database analyses. These studies are subject to confounding: patients prescribed fluoroquinolones for respiratory infections may have underlying conditions — hypertension, atherosclerosis, connective tissue disorders — that independently elevate aortic risk. Researchers have attempted to control for these variables, but residual confounding cannot be excluded.

Similarly, the peripheral neuropathy signal, while biologically plausible given fluoroquinolone effects on mitochondrial function, remains difficult to quantify precisely in observational data. Neuropathy has many causes, and disentangling drug-induced cases from background incidence requires methodological rigor that not all published studies achieve.

None of this means the risks are fabricated or negligible. It means they should be interpreted with the same epistemic care applied to any observational pharmacoepidemiological finding. The FDA's actions suggest the agency views the evidence as sufficient to warrant strong warnings and restricted use — not sufficient to justify removal.

The Path Forward: Narrowing Use Without Losing a Tool

The most constructive framing of the ciprofloxacin paradox may not be "why is this drug still available" but rather "how do we use it more precisely." The drug's continued presence on the market reflects a genuine clinical need that has not been fully addressed by alternative antibiotics. The problem is not the drug's existence but its overuse in scenarios where that need is absent.

Antibiotic stewardship programs with explicit fluoroquinolone-sparing protocols have demonstrated measurable reductions in inappropriate use in hospital settings. Extending that infrastructure to outpatient and urgent care environments — where the majority of inappropriate ciprofloxacin prescribing occurs — represents the most realistic mechanism for meaningful change.

For patients and clinicians navigating this landscape, the essential question before each prescription is not whether ciprofloxacin works, but whether it is the right tool for this specific infection in this specific patient. The answer to that question, applied consistently and rigorously, may accomplish more than any regulatory action alone.